Carrington Laboratories Announces Stock Repurchase Plan

Apr 03, 2001, 01:00 ET from Carrington Laboratories, Inc.

    IRVING, Texas, April 3 /PRNewswire/ --
 Carrington Laboratories, Inc. (Nasdaq: CARN) announced that its Board of
 Directors has authorized a stock repurchase plan allowing the Company to
 purchase up to one million shares of the Company's common stock.  The shares
 may be purchased by Carrington from time to time in the open market or through
 negotiated private transactions.  The number of shares purchased and the
 timing of purchases will be dependent on a number of factors, including the
 market price of the shares and market and business conditions.
     "The Board's adoption of this program reflects our confidence in the
 future of Carrington and our commitment to enhancing shareholder value,"
 stated Carlton Turner, Carrington's president and CEO.  "We believe that our
 stock is currently undervalued and, at prevailing price levels, Carrington
 stock presents an attractive investment opportunity."
     Turner continued, "With an anticipated profit for the first quarter, a
 steadily improving cash position and available borrowing capacity, we are
 delighted to be in a position to strengthen our commitment to our business,
 our shareholders and our future."
     Carrington Laboratories, Inc., is an ISO 9001-certified, research-based
 biopharmaceutical company currently utilizing naturally-occurring complex
 carbohydrates to manufacture and market products for mucositis, radiation
 dermatitis, wound and oral care; manufacture and market the nutraceutical raw
 material Manapol(R) and cosmetic-grade raw material Hydrapol(TM); and market
 consumer products under the AloeCeuticals(R) brand.  Carrington's technology
 is protected by more than 119 patents in 26 countries.  Select products are
 honored with the internationally coveted CE mark, recognized by more than
 20 countries around the world.
     Certain statements in this release concerning Carrington may be forward-
 looking.  Actual events will be dependent upon a number of factors and risks
 including, but not limited to: subsequent changes in plans by the Company's
 management; delays or problems in production; changes in the regulatory
 process; changes in trends; and a number of other factors and risks described
 from time to time in the Company's filings with the Securities & Exchange
 Commission, including the Form 10Q filed April 2, 2001.
 
 

SOURCE Carrington Laboratories, Inc.
    IRVING, Texas, April 3 /PRNewswire/ --
 Carrington Laboratories, Inc. (Nasdaq: CARN) announced that its Board of
 Directors has authorized a stock repurchase plan allowing the Company to
 purchase up to one million shares of the Company's common stock.  The shares
 may be purchased by Carrington from time to time in the open market or through
 negotiated private transactions.  The number of shares purchased and the
 timing of purchases will be dependent on a number of factors, including the
 market price of the shares and market and business conditions.
     "The Board's adoption of this program reflects our confidence in the
 future of Carrington and our commitment to enhancing shareholder value,"
 stated Carlton Turner, Carrington's president and CEO.  "We believe that our
 stock is currently undervalued and, at prevailing price levels, Carrington
 stock presents an attractive investment opportunity."
     Turner continued, "With an anticipated profit for the first quarter, a
 steadily improving cash position and available borrowing capacity, we are
 delighted to be in a position to strengthen our commitment to our business,
 our shareholders and our future."
     Carrington Laboratories, Inc., is an ISO 9001-certified, research-based
 biopharmaceutical company currently utilizing naturally-occurring complex
 carbohydrates to manufacture and market products for mucositis, radiation
 dermatitis, wound and oral care; manufacture and market the nutraceutical raw
 material Manapol(R) and cosmetic-grade raw material Hydrapol(TM); and market
 consumer products under the AloeCeuticals(R) brand.  Carrington's technology
 is protected by more than 119 patents in 26 countries.  Select products are
 honored with the internationally coveted CE mark, recognized by more than
 20 countries around the world.
     Certain statements in this release concerning Carrington may be forward-
 looking.  Actual events will be dependent upon a number of factors and risks
 including, but not limited to: subsequent changes in plans by the Company's
 management; delays or problems in production; changes in the regulatory
 process; changes in trends; and a number of other factors and risks described
 from time to time in the Company's filings with the Securities & Exchange
 Commission, including the Form 10Q filed April 2, 2001.
 
 SOURCE  Carrington Laboratories, Inc.